Abstract
Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (P
Conclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol.
Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study.
Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective.
| Original language | English |
|---|---|
| Pages (from-to) | 1-6 |
| Number of pages | 6 |
| Journal | International Journal of Nephrology and Renovascular Disease |
| Volume | 8 |
| DOIs | |
| Publication status | Published - Dec 16 2014 |
Fingerprint
Keywords
- Cost consequences analysis
- Outcomes
- Secondary hyperparathyroidism
- SHPT treatments
- Therapeutic costs
ASJC Scopus subject areas
- Nephrology
Cite this
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients : The FARO-2 study. / Roggeri, Daniela Paola; Cozzolino, Mario; Mazzaferro, Sandro; Brancaccio, Diego; Paoletti, Ernesto; Roggeri, Alessandro; Costanzo, Anna Maria; Paparatti, Umberto di Luzio; Festa, Vincenzo; Messa, Piergiorgio.
In: International Journal of Nephrology and Renovascular Disease, Vol. 8, 16.12.2014, p. 1-6.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients
T2 - The FARO-2 study
AU - Roggeri, Daniela Paola
AU - Cozzolino, Mario
AU - Mazzaferro, Sandro
AU - Brancaccio, Diego
AU - Paoletti, Ernesto
AU - Roggeri, Alessandro
AU - Costanzo, Anna Maria
AU - Paparatti, Umberto di Luzio
AU - Festa, Vincenzo
AU - Messa, Piergiorgio
PY - 2014/12/16
Y1 - 2014/12/16
N2 - Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (PConclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol.Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study.Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective.
AB - Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (PConclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol.Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study.Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective.
KW - Cost consequences analysis
KW - Outcomes
KW - Secondary hyperparathyroidism
KW - SHPT treatments
KW - Therapeutic costs
UR - http://www.scopus.com/inward/record.url?scp=84919679892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919679892&partnerID=8YFLogxK
U2 - 10.2147/IJNRD.S72011
DO - 10.2147/IJNRD.S72011
M3 - Article
AN - SCOPUS:84919679892
VL - 8
SP - 1
EP - 6
JO - International Journal of Nephrology and Renovascular Disease
JF - International Journal of Nephrology and Renovascular Disease
SN - 1178-7058
ER -